Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Other Accumulated Expenses: 2020-2025

Historic Other Accumulated Expenses for SAB Biotherapeutics (SABS) over the last 4 years, with Sep 2025 value amounting to $1.6 million.

  • SAB Biotherapeutics' Other Accumulated Expenses fell 4.56% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 4.56%. This contributed to the annual value of $521,639 for FY2024, which is 8.58% up from last year.
  • Latest data reveals that SAB Biotherapeutics reported Other Accumulated Expenses of $1.6 million as of Q3 2025, which was up 100.51% from $808,363 recorded in Q2 2025.
  • SAB Biotherapeutics' Other Accumulated Expenses' 5-year high stood at $1.7 million during Q3 2024, with a 5-year trough of $200,000 in Q1 2023.
  • Moreover, its 3-year median value for Other Accumulated Expenses was $521,639 (2024), whereas its average is $674,315.
  • Per our database at Business Quant, SAB Biotherapeutics' Other Accumulated Expenses crashed by 40.59% in 2023 and then surged by 708.69% in 2024.
  • Over the past 5 years, SAB Biotherapeutics' Other Accumulated Expenses (Quarterly) stood at $283,909 in 2021, then soared by 80.73% to $513,110 in 2022, then fell by 6.37% to $480,435 in 2023, then grew by 8.58% to $521,639 in 2024, then dropped by 4.56% to $1.6 million in 2025.
  • Its Other Accumulated Expenses was $1.6 million in Q3 2025, compared to $808,363 in Q2 2025 and $743,100 in Q1 2025.